Company profile: ArsenalBio
1.1 - Company Overview
Company description
- Provider of programmable CAR T-cell therapies for solid tumors, using synthetic biology to engineer T cells, including AB-1015 for ovarian cancer with dual antigen-sensing logic gating, AB-2100 for kidney cancer with potency enhancements, and the AB-3000 series for prostate cancer; collaborates with Bristol Myers Squibb and Genentech to advance next-generation T-cell therapies.
Products and services
- Programmable T Cells: ArsenalBio architects custom-engineered T cells that are genetically programmed to potentially eradicate solid tumors, using synthetic biology to install defined therapeutic actions
- AB-3000 series: Potency-optimized CAR T-cell products for prostate cancer that integrate logic gating and additional modifications to increase anti-tumor potency
- AB-1015: A logic-gated, dual antigen sensing CAR T-cell therapy engineered for ovarian cancer that enhances tumor specificity and safety via a dual antigen logic gate
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ArsenalBio
Acousia Therapeutics
HQ: Germany
Website
- Description: Provider of small-molecule therapeutics for sensorineural hearing loss, with expertise in identifying and developing drug candidates to enhance and preserve natural hearing. Products include ACOU085, an etiology-agnostic otoprotective candidate preventing chemotherapy-induced hearing loss and sensory hair cell death, and ACOU082, an oral Kv7.4 activator to enhance natural hearing and protect against age-related loss.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acousia Therapeutics company profile →
Cell Design Labs
HQ: United States
Website
- Description: Provider of biotherapeutic, cell-based therapy development for cancer and other devastating diseases, leveraging the body's immune system to create smart, living therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cell Design Labs company profile →
Universal Cells
HQ: United States
Website
- Description: Provider of nuclease-free rAAV gene editing technology to create universal donor pluripotent and engineered allogeneic stem cells, and cell production for clinical trials. Develops, licenses and commercializes stem cell therapies designed to overcome immune rejection and enable true off-the-shelf therapeutic products using a proprietary genome editing approach.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Universal Cells company profile →
Orthofix
HQ: United States
Website
- Description: Provider of medical devices and digital solutions for spine procedures (alignment, disc height improvement, nerve decompression, instability correction); biologics including viable-cell allografts, structural allografts, synthetic bone grafts, and amniotic membranes; PEMF bone growth therapy for spinal fusion and nonunion fractures; and the Fitbone motorized intramedullary nail for femur/tibia transport or lengthening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orthofix company profile →
Xintela
HQ: Sweden
Website
- Description: Provider of regenerative medicine and cancer therapies, including XSTEM, a stem cell product selected via integrin α10β1 for treating diseases such as knee osteoarthritis and venous leg ulcers; EQSTEM, a stem cell therapy for horses targeting osteoarthritis and degenerative joint diseases; and therapeutic antibodies against integrin α10β1 for certain cancers, including triple-negative breast cancer and glioblastoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xintela company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ArsenalBio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ArsenalBio
2.2 - Growth funds investing in similar companies to ArsenalBio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ArsenalBio
4.2 - Public trading comparable groups for ArsenalBio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →